Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Deciphering a clinical-stage biotech filing can feel like running a lab experiment without the protocol. Vor Biopharma’s 10-K spans pages of gene-editing details, cash-burn tables, and licensing clauses that leave many investors asking, “Where do I start?”
Stock Titan answers with AI-powered clarity. Our platform scans every new document the second it lands on EDGAR—whether it’s an 8-K material events notice on fresh trial data or a Form 4 insider transaction that hints at executive sentiment. Type a natural question like “understanding Vor Biopharma SEC documents with AI” or “how to read the Vor Biopharma annual report 10-K simplified,” and get plain-English summaries, key financial metrics, and direct page links within seconds.
Here’s what you can explore in one dashboard:
- Vor Biopharma quarterly earnings report 10-Q filing—AI highlights shifts in R&D spend and runway.
- Vor Biopharma insider trading Form 4 transactions—real-time alerts on buys, sells, and option grants.
- Vor Biopharma proxy statement executive compensation—breakdowns of equity awards tied to clinical milestones.
- Vor Biopharma 8-K material events explained—speed-read summaries of trial pauses, FDA designations, or financing rounds.
Need deeper context? Our AI cross-references historical filings for trendlines, delivering a concise Vor Biopharma earnings report filing analysis with year-over-year R&D and dilution impacts. Investors monitoring “Vor Biopharma Form 4 insider transactions real-time” or evaluating risk factors no longer have to sift through biotech jargon—Stock Titan surfaces what matters so you can focus on decisions, not documents.
Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.
- Securities for sale: 29,432 common shares.
- Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
- Proposed sale date: 08 / 04 / 2025 on NASDAQ.
- Aggregate market value of planned sale: $61,589.40.
- Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
- Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.
No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR’s capital structure.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
